Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

Quote

Yes. Let me try again.

(1) Was the lesion reduced by >20% at 48-72 hours? Yes/No
<<yes.
(2) What percentage of patients from each arm had their lesions reduced by >20%? (responders/total in arm)
<<100 percent
(3) How does each Brilacidin arm statistically compare to the control arm (daptomycin)?
<<Statistical comparisons between B and D arms were made through the secondary outcome measures as shown below.

Clinical Response [ Time Frame: Day 7-8; Day 10-14; Day 21-28 ] [ Designated as safety issue: No ]
For Days 7/8 and 10-14, a response of Clinical Success will be assigned if all signs and symptoms of infection present at baseline have improved and/or resolved and no additional antibiotics are considered necessary. Subjects who have a response of Clinical Success at Day 10-14 will be assessed for sustained efficacy at Day 21-28. A response of Sustained Clinical Success will be assigned if all signs and symptoms remain resolved and no additional antibiotics are considered necessary. If signs and symptoms of infection recurred at the original site of infection and require additional antibiotic therapy, a response of Relapse will be assigned.